Influence of Sevoflurane on the Metabolism and Renal Effects of Compound A in Rats

Background:The sevoflurane degradation product compound A is nephrotoxic in rats. In contrast, patient exposure to compound A during sevoflurane anesthesia has no clinically significant renal effects. The mechanism for this difference is incompletely understood. One possibility is that the metabolism and toxicity of compound A in humans is prevented by sevoflurane. However, the effect of sevoflurane on compound A metabolism and nephrotoxicity is unknown. Thus, the purpose of this investigation was to determine the effect of sevoflurane on the metabolism and renal toxicity of compound A in rats. Methods:Male rats received 0.25 mmol/kg intraperitoneal compound A, alone and during sevoflurane anesthesia (3%, 1.3 minimum alveolar concentration, for 3 h). Compound A metabolites in urine were quantified, and renal function was evaluated by serum creatinine and urea nitrogen, urine volume, osmolality, protein excretion, and renal tubular histology. Results:Sevoflurane coadministration with compound A inhibited compound A defluorination while increasing relative metabolism through pathways of sulfoxidation and β-lyase–catalyzed metabolism, which mediate toxicity. Sevoflurane coadministration with compound A increased some (serum creatinine and urea nitrogen, and necrosis) but not other (urine volume, osmolality, and protein excretion) indices of renal toxicity. Conclusions:Sevoflurane does not suppress compound A nephrotoxicity in rats in vivo. These results do not suggest that lack of nephrotoxicity in surgical patients exposed to compound A during sevoflurane anesthesia results from an inhibitory effect of sevoflurane on compound A metabolism and toxicity. Rather, these results are consistent with differences between rats and humans in compound A exposure and inherent susceptibility to compound A nephrotoxicity.

[1]  H. Mehendale,et al.  Dose-dependent liver tissue repair after chloroform plus trichloroethylene binary mixture. , 2005, Basic & clinical pharmacology & toxicology.

[2]  M. W. Anders.  Formation and toxicity of anesthetic degradation products. , 2005, Annual review of pharmacology and toxicology.

[3]  H. D. Liggitt,et al.  Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. , 2004, Chemical research in toxicology.

[4]  O. Yuge,,et al.  A Comparison of the Effects of Prolonged (>10 Hour) Low-flow Sevoflurane, High-flow Sevoflurane, and Low-flow Isoflurane Anaesthesia on Hepatorenal Function in Orthopaedic Patients , 2004, Anaesthesia and intensive care.

[5]  E. Kharasch,et al.  Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A). , 2004, Chemical research in toxicology.

[6]  E. Kharasch,et al.  Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. , 2003, Toxicology and applied pharmacology.

[7]  E. Eger,et al.  Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven. , 2003, Anesthesiology.

[8]  A. Artru,et al.  Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. , 2002, Anesthesiology.

[9]  E. Kharasch,et al.  Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catal , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  A. Artru,et al.  Long-Duration Low-Flow Sevoflurane and Isoflurane Effects on Postoperative Renal and Hepatic Function , 2001, Anesthesia and analgesia.

[11]  E. Kharasch,et al.  Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro. , 2001, Toxicology and applied pharmacology.

[12]  T. Ebert,et al.  Renal Responses to Low-flow Desflurane, Sevoflurane, and Propofol in Patients , 2000, Anesthesiology.

[13]  T. Katoh,et al.  The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. , 2000, Anesthesia and analgesia.

[14]  E. Kharasch,et al.  Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison. , 1999, Anesthesiology.

[15]  E. Kharasch,et al.  Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats. , 1999, Toxicology and applied pharmacology.

[16]  H. Higuchi,et al.  Effects of Sevoflurane and Isoflurane on Renal Function and on Possible Markers of Nephrotoxicity , 1998, Anesthesiology.

[17]  E. Kharasch,et al.  Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats. , 1998, Anesthesiology.

[18]  M. W. Anders,et al.  Cysteine Conjugate beta‐Lyase‐Dependent Metabolism of Compound A (2‐[fluoromethoxy]‐1,1,3,3,3‐pentafluoro‐1‐propene) in Human Subjects Anesthetized with Sevoflurane and in Rats Given Compound A , 1998, Anesthesiology.

[19]  R. Baggs,et al.  Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3, 3-pentafluoro-1-propene (Compound A) in male Fischer 344 rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[20]  E. Kharasch,et al.  Role of Renal Cysteine Conjugate beta‐Lyase in the Mechanism of Compound A Nephrotoxicity in Rats , 1997, Anesthesiology.

[21]  M. W. Anders,et al.  Cysteine Conjugate beta-Lyase-dependent Biotransformation of the Cysteine S-Conjugates of the Sevoflurane Degradation Product Compound A in Human, Nonhuman Primate, and Rat Kidney Cytosol and Mitochondria , 1996, Anesthesiology.

[22]  E. Kharasch,et al.  Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase. , 1996, Chemical research in toxicology.

[23]  E. Kharasch,et al.  P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product. , 1996, Drug Metabolism And Disposition.

[24]  K. Ikeda,et al.  Renal and Hepatic Function in Surgical Patients After Low-Flow Sevoflurane or Isoflurane Anesthesia , 1996, Anesthesia and analgesia.

[25]  P. Prokocimer,et al.  Inhalation Toxicity Study of a Haloalkene Degradant of Sevoflurane, Compound A (PIFE), in Sprague‐Dawley Rats , 1995, Anesthesiology.

[26]  Y. Ogasawara,et al.  Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. , 1992, Anesthesiology.

[27]  M. Malcomson,et al.  Quantification of the degradation products of sevoflurane in two CO2 absorbants during low-flow anesthesia in surgical patients. , 1992, Anesthesiology.

[28]  J. Heavner,et al.  HYPERCARBIA AND HYPOXIA ENHANCE BUPIVACAINE TOXICITY IN YOUNG PIGS , 1992 .

[29]  S. Morgan,et al.  Plasma Inorganic Fluoride Ion Concentrations with Sevoflurane Anesthesia in obese and Nonobese Subjects , 1992 .

[30]  M. Ikeda,et al.  Dose-excretion relationship in tetrachloroethylene-exposed workers and the effect of tetrachloroethylene co-exposure on trichloroethylene metabolism. , 1989, American journal of industrial medicine.

[31]  T. L. Cook,et al.  A Comparison of Renal Effects and Metabolism of Sevoflurane and Methoxyflurane in Enzyme‐Induced Rats , 1975, Anesthesia and analgesia.

[32]  T. L. Cook,et al.  Renal Effects and Metabolism of Sevoflurane in Fischer 344 Rats: An In‐vivo and In‐vitro Comparison with Methoxyflurane , 1975, Anesthesiology.